Pettengell, Ruth2; Schmitz, Norbert2; Gisselbrecht, Christian2; Smith, Graeme2; Patton, William N2; Metzner, Bernd2; Caballero, Dolores2; Tilly, Herve2; Walewski, Jan A2; Bence-Bruckler, Isabelle2; To, Bik2; Geisler, Christian H3; Schots, Rik2; Kimby, Eva2; Taverna, Christian J2; Kozák, Tomás2; Dreger, Peter2; Uddin, Ruzena2; Ruiz de Elvira, Carmen2; Goldstone, Anthony H2
1 Section of Surgery and Internal Medicine, Department of Clinical Medicine, Faculty of Health and Medical Sciences, Københavns Universitet2 unknown3 Section of Surgery and Internal Medicine, Department of Clinical Medicine, Faculty of Health and Medical Sciences, Københavns Universitet
a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation
The objective of this randomized trial was to assess the efficacy and safety of rituximab as in vivo purging before transplantation and as maintenance treatment immediately after high-dose chemotherapy and autologous stem-cell transplantation (HDC-ASCT) in patients with relapsed follicular lymphoma (FL).
Journal of Clinical Oncology, 2013, Vol 31, Issue 13, p. 1624-30